SEC Form 6-K filed by Medicenna Therapeutics Corp.

11/21/23 10:39:11 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $MDNA alert in real time by email

6-K 1 tm2331073d1_6k.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2023

Commission File Number: 001-39458

Medicenna Therapeutics Corp.

(Translation of registrant’s name into English)

2 Bloor St. W. 7^th Floor

Toronto, Ontario M4W 3E2

Canada

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

x Form 20-F

¨ Form 40-F

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Medicenna Therapeutics Corp.
	(Registrant)


Date: November 21, 2023	By:	/s/ Fahar Merchant
		Name:	Fahar Merchant, PhD
		Title:	Chief Executive Officer

Form 6-K Exhibit Index

Exhibit Number		Document Description

99.1		Press Release of the Registrant dated November 17, 2023

Get the next $MDNA alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MDNA

Date	Price Target	Rating	Analyst

More analyst ratings

Medicenna Therapeutics to Provide Clinical Update from Phase 1/2 ABILITY Study on August 9, 2023
TORONTO and HOUSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1/2 ABILITY study evaluating MDNA11 in patients with melanoma and other select tumors. Shareholders and financial analysts are invited to join the live audio webcast either by phone or through the webcast link. Both options to connect to the webcast are described on Medicenna's website: https://ir.medicenna.com/news-and-events/events-and-presentations The webcast will b
8/4/23 7:00:00 AM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Medicenna Reports First Quarter Fiscal 2024 Financial Results and Operational Highlights
Safety Review Committee clears MDNA11 Cohort 6 dose of 120µg/Kg, Q2W, in the Phase 1 portion of the ABILITY Study as there were no protocol defined dose-limiting toxicitiesMDNA11 clinical update scheduled for August 9; conference call to discuss data from cohorts five and six, recommended dose for monotherapy expansion and details on Phase 2 trial design$29.6 million in cash and cash equivalents as of June 30, 2023 provides expected runway through the completion of the ABILITY study and through calendar Q3 2024 TORONTO and HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy compa
7/28/23 7:00:00 AM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Medicenna Reports Third Quarter Fiscal 2023 Financial Results and Operational Highlights
Phase 1/2 ABILITY study advancing to sixth dose escalation cohort following positive review of safety and pharmacodynamic data from fifth cohort Initial PK/PD data from ABILITY's fifth dose escalation cohort expected alongside updated anti-tumor data in calendar Q1 2023$36.2 million in cash and cash equivalents at December 31, 2022 provides expected runway through the completion of the ABILITY study and through calendar Q2 2024 Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (NASDAQ:MDNA, TSX:MDNA), a clinical stage immunotherapy company, today announced it
2/7/23 7:00:24 AM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care

$MDNA
Leadership Updates

Live Leadership Updates

Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
TORONTO and HOUSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company focused on the development of novel Superkines, today announced the appointment of Humphrey Gardner, M.D., as Chief Medical Officer (CMO) to lead the development strategy and execution of Medicenna's clinical programs. "We are thrilled to welcome Dr. Gardner as Medicenna's new CMO and member of our management team. Dr. Gardner holds remarkable leadership experiences advancing immune-based therapies for cancer and other diseases from the earliest stages of development through regulatory approvals," said Fahar Merc
10/10/23 7:07:53 AM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Medicenna Announces Results of Annual and Special Meeting of Shareholders
TORONTO and HOUSTON, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") ((NASDAQ, TSX:MDNA), a clinical-stage immuno-oncology company focused on the development of novel Superkines, today announced the voting results from the Company's annual and special meeting of shareholders held today, September 28, 2023 (the "Meeting"). Medicenna is pleased to announce that all of the nominees listed in the management information circular dated August 9, 2023 (the "Circular"), were elected as directors. Each director was elected with greater than 97% of the votes cast by shareholders present at the Meeting or represented by proxy. The results of the vote
9/28/23 5:00:00 PM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Medicenna Announces the Appointment of Jeff Caravella as Chief Financial Officer
Jeff Caravella brings over two decades of healthcare expertise steering strategic, financial and operational functions at leading public life-science corporations Mr. Caravella's appointment demonstrates Medicenna's continuing commitment to establish its presence in Boston, the leading biotechnology ecosystem TORONTO and HOUSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (NASDAQ:MDNA, TSX:MDNA), a clinical-stage immunotherapy company, today announced the appointment of Jeff Caravella as Chief Financial Officer (CFO). In this position, Mr. Caravella will lead Medicenna's financial strategy to support the Company's growth. This appointmen
8/28/23 7:00:57 AM ET
$EDIT
$MDNA
$TNGX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Biotechnology: Pharmaceutical Preparations

Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual Meeting
TORONTO and HOUSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTC:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. The highlights of the data set will be presented by: Dr Steven Brem, M.D., Medical Director, Centre for Precisio
11/9/23 8:56:49 AM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
MDNA11 continues to demonstrate encouraging single-agent activity from the dose escalation and evaluation portion of the ABILITY-1 Study including deep ongoing partial responses with 100% reduction of target lesions in one pancreatic and 70% reduction of target lesion in one melanoma cancer patientMDNA11 also showed durable stable disease in 3 melanoma patients for at least 5 months to 18 months with concomitant shrinkage of tumor size following failure with check-point inhibitor therapiesMDNA11 is generally well tolerated with no dose-limiting toxicities or vascular leak syndrome reported in any of the dose escalation cohortsMedicenna believes that these data reaffirm the differentiated and
11/6/23 7:00:00 AM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymes IL-13Rα2 is overexpressed by some of the most immunologically "cold" tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patients TORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Com
11/3/23 12:00:00 PM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care

$MDNA
Market Insights

Live Market Insights

Medicenna To Present 4 Year Follow-Up Phase 2b Bizaxofusp Survival Data In Recurrent Glioblastoma At The Society For Neuro-Oncology 2023 Annual Meeting
Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (TSX:MDNA, OTC:MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, today announced that a poster presentation and an oral summary highlighting long-term follow up from the Phase 2b clinical trial of bizaxofusp (formerly known as MDNA55), the Company's first-in-class IL-4R targeted therapy, will be presented at the Society for Neuro-Oncology (SNO) 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. The highlights of the data set will be presented by:Dr Steven Brem, M.D., Medical Director, Centre for Precision Surgery, Abramson Cancer Center, Perelman School of Medici
11/9/23 9:15:45 AM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Medicenna Presents Preclinical Data On MDNA113, Its Targeted Metalloprotease Activated SuperKine At The 38th Annual Meeting Of The Society For Immunotherapy Of Cancer
Company's T-MASK platform demonstrates ability to maximize anti-tumor efficacy and minimize systemic toxicity, and opportunities to explore broad range of cytokines and other potent therapeutics MDNA113 is a first-in-class IL-13R⍺2 targeted therapy that delivers a masked bi-specific IL-2-AntiPD1 Superkine to the tumor micro-environment where it is activated by cancer specific enzymesIL-13Rα2 is overexpressed by some of the most immunologically "cold" tumors with high unmet needs in pancreatic, liver, brain, breast and prostate cancer that annually affect over 2 million patientsTORONTO and HOUSTON, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or the "Company") (
11/3/23 12:13:33 PM ET
$MDNA
Biotechnology: Pharmaceutical Preparations
Health Care
Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
Gainers Miromatrix Medical Inc. (NASDAQ:MIRO) shares jumped 232% to $3.36 in pre-market trading. United Therapeutics Corporation (NASDAQ:UTHR) agreed to acquire Miromatrix Medical for $3.25 per share in cash (an aggregate of approximately $91 million). Conduit Pharmaceuticals Inc. (NASDAQ:CDT) shares surged 70.6% to $1.74 in pre-market trading after falling more than 12% on Friday. reAlpha Tech Corp. (NASDAQ:AIRE) shares gained 22% to $28.26 in pre-market trading after dipping around 54% on Friday. My Size, Inc. (NASDAQ:MYSZ) shares climbed 21.4% to $0.8498 in pre-market trading. Coherus BioSciences, Inc. (NASDAQ:CHRS) shares rose 16.2% to $3.07 in pre-market trading. Coherus and Junsh
10/30/23 8:44:55 AM ET
$AIRE
$BGNE
$BKYI
$BPTS
Real Estate
Finance
Biotechnology: Pharmaceutical Preparations
Health Care